Fredrikson & Byron acted as legal counsel to Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, in its acquisition of Asuragen Inc., a leader in the development, manufacturing and commercialization of genetic carrier screening and oncology testing kits for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones. Bio-Techne anticipates the acquisition to close in the fourth quarter of its fiscal 2021.
Fredrikson’s legal team included Ryan Brauer, Zach Olson, Aleida Conners and Tash Bottum.
Read the news release.
